Navigation Links
Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
Date:5/29/2012

JERUSALEM, May 29, 2012 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the New Zealand Patent Office. The patent, entitled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's technology. Oramed's portfolio now consists of three issued patents and 34 patents pending for its technologies and products.

Exenatide is a GLP-1 analogue, and is a highly effective medication for the management of Type 2 diabetes (T2DM). The physiological pathways it engages to lower blood glucose levels generate a sparing impact on the pancreatic beta cells, blunting their gradual exhaustion - a typical marker of late-stage T2DM. In addition to the drug's intrinsic benefits, results with Oramed's oral exenatide formula did not induce nausea among volunteers - a debilitating side effect of exenatide injections - presenting  an advantage that could have a considerable impact on the use of this drug. Trials evaluating the safety and efficacy Oramed's GLP-1 analog formulation in diabetic patients are planned to commence in Q3 2012. 

Nadav Kidron, CEO of Oramed, commented: "We are very pleased with this news regarding our third patent approval and the inclusion of New Zealand in our global patent network. This particular patent - the first on our oral exenatide formulation - allows Oramed to gain yet more ground in the biotechnology world. We look forward to more patents being approved in the future."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection.

Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials, and with its GLP-1 analog capsule, currently entering Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit http://www.oramed.com 

SafeHarbor for Forward-Looking Statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our expectations for additional patents, our technologies and their validation and the possibility of increased patient compliance resulting from our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company and Investor Relations Contact:
Aviva Sherman
USA: +1-646-240-4193
Int'l: +-972-2-566-0001
+972-54-792-4438
E-mail: aviva@oramed.com



'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
2. Oramed Pharmaceuticals Granted Australian Patent for Important Part of the Companys Core Technology in Oral Delivery of Proteins
3. Oramed Pharmaceuticals Files US Patent Application for Combination Oral Treatment of Diabetes
4. Oramed Pharmaceuticals Announces Successful Phase 1 Clinical Trial Results for EnteraBio
5. Oramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011
6. Oramed Pharmaceuticals to Present at Rodman & Renshaw 13th Annual Global Investment Conference
7. Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
8. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
9. Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
10. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
11. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... capillary electrophoresis market to grow at a CAGR of 7.06% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:3/23/2017)... 23, 2017  Drug diversion is a significant ... deadly overdoses. A new oral fluid monitoring test, ... , reports more detailed and actionable information to ... improve therapy adherence, patient safety, and help to ... Oral fluid Rx Evaluation (CORE) system is the ...
(Date:3/23/2017)... SAN DIEGO , March 23, 2017 /PRNewswire/ ... for fast and accurate identification of individuals who ... at risk for a rare yet potentially deadly ... seizures and bipolar disorder.  The gene HLA-B*15:02 ... hypersensitivity reactions such as Stevens-Johnson syndrome and toxic ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National ... preparation programs. The NCTQ report suggests, based on a review of GPA and SAT/ACT ... teacher quality in the U.S. It argues that this higher bar should be set ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
(Date:3/23/2017)... and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of ... industry or whose acts have had a significant impact on the careers of all others ... Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. The induction ...
(Date:3/23/2017)... ... 23, 2017 , ... March is National Kidney Month – the perfect time ... to maintaining good health. Every day, two kidneys filter about 120 to 150 quarts ... your blood, eliminating waste, regulating fluid levels and blood pressure, supporting bone health and ...
(Date:3/23/2017)... ... March 23, 2017 , ... Hakim Unique Group (HUG) ... company California Healthcom Group (CHG). , The HUG investment is a landmark ... in California, CHG is a growing, internationally recognized healthcare management, technology, and services ...
Breaking Medicine News(10 mins):